NAS:OPNT (USA) Also trade in: Germany

Opiant Pharmaceuticals Inc

$ 13.7 -0.28 (-2%)
Volume: 17,760 Avg Vol (1m): 20,859
Market Cap $: 54.73 Mil Enterprise Value $: 30.96 Mil
P/E (TTM): 0.00 P/B: 3.19
Earnings Power Value -665.79
Net Current Asset Value 4.29
Tangible Book 4.29
Projected FCF 1.84
Median P/S Value 16.56
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
85.90% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
OPNT: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.01, Med: 10000, Max: 10000
Current: 10000
0.01
10000
Equity-to-Asset 0.64
Equity-to-Asset ranked lower than
76.28% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
OPNT: 0.64
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -18.7, Med: 0.01, Max: 0.86
Current: 0.64
-18.7
0.86
Interest Coverage No Debt
Interest Coverage ranked higher than
82.60% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
OPNT: No Debt
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 1773.25, Med: 10000, Max: 10000
Current: 10000
1773.25
10000
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.79
DISTRESS
GREY
SAFE
Beneish M-Score -3.40
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 3.99%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -77.41
Operating Margin ranked lower than
62.63% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
OPNT: -77.41
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -445.1, Med: -114.87, Max: 38.45
Current: -77.41
-445.1
38.45
Net Margin % -76.71
Net Margin ranked lower than
63.51% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
OPNT: -76.71
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -454.06, Med: -115.27, Max: 35.68
Current: -76.71
-454.06
35.68
ROE % -92.91
ROE ranked lower than
95.55% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
OPNT: -92.91
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -200.02, Med: -200.02, Max: -92.91
Current: -92.91
-200.02
-92.91
ROA % -59.87
ROA ranked lower than
93.17% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
OPNT: -59.87
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -20196.75, Med: -2432.84, Max: 103.72
Current: -59.87
-20196.75
103.72
ROC (Joel Greenblatt) % -9314.54
ROC (Joel Greenblatt) ranked lower than
99.52% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
OPNT: -9314.54
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1412666.67, Med: -221085.71, Max: 141860
Current: -9314.54
-1412666.67
141860
3-Year Total Revenue Growth Rate 108.20
3-Year Revenue Growth Rate ranked lower than
100.00% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
OPNT: 76.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 76.3
Current: 76.3
0
76.3
3-Year Total EBITDA Growth Rate -44.60
3-Year EBITDA Growth Rate ranked higher than
60.72% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
OPNT: -22.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate -22.30
3-Year EPS w/o NRI Growth Rate ranked higher than
57.54% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
OPNT: -22.3
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» OPNT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:OPNT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare TSE:4585 LSE:DEST ROCO:4186 ROCO:6580 OTCPK:PMCB OSTO:ASAP NAS:BVXV NAS:VTGN OSTO:MVIR B NAS:CLDX TSE:6090 OTCPK:CNBX NAS:ALRN NAS:VBLT NAS:BLPH NAS:ICCC NAS:CLSD LSE:C4XD LSE:MTPH XCNQ:MYM
Traded in other countries 8OP.Germany
Address 201 Santa Monica Boulevard, Suite 500, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The pipeline product of the company candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine.

Ratios

Current vs industry vs history
Forward PE Ratio 31.75
Forward P/E ranked lower than
100.00% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
OPNT: 31.75
Ranked among companies with meaningful Forward P/E only.
N/A
PB Ratio 3.19
PB Ratio ranked lower than
67.26% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
OPNT: 3.19
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.77, Med: 3.49, Max: 1651.3
Current: 3.19
1.77
1651.3
PS Ratio 2.56
PS Ratio ranked higher than
65.29% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
OPNT: 2.56
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.74, Med: 3.11, Max: 33.06
Current: 2.56
0.74
33.06
EV-to-EBIT -2.26
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
OPNT: -2.26
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -3, Med: -1.4, Max: 34.5
Current: -2.26
-3
34.5
EV-to-EBITDA -2.26
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
OPNT: -2.26
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -3, Med: -1.4, Max: 34.4
Current: -2.26
-3
34.4
EV-to-Revenue 1.74
EV-to-Revenue ranked higher than
71.47% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
OPNT: 1.74
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.1, Med: 2.6, Max: 31.2
Current: 1.74
0.1
31.2
Current Ratio 2.77
Current Ratio ranked lower than
69.09% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
OPNT: 2.77
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.01, Med: 0.41, Max: 7.86
Current: 2.77
0.01
7.86
Quick Ratio 2.77
Quick Ratio ranked lower than
65.92% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
OPNT: 2.77
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.01, Med: 0.41, Max: 7.86
Current: 2.77
0.01
7.86
Days Sales Outstanding 40.31
Days Sales Outstanding ranked lower than
79.79% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
OPNT: 40.31
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 11.51, Med: 74.2, Max: 117.19
Current: 40.31
11.51
117.19
Days Payable 35.55
Days Payable ranked lower than
100.00% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
OPNT: 35.55
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 27.18, Med: 27.18, Max: 35.55
Current: 35.55
27.18
35.55

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -17.50
3-Year Share Buyback Rate ranked higher than
71.76% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
OPNT: -17.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -38.6, Med: -6.4, Max: 22.1
Current: -17.5
-38.6
22.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.19
Price-to-Tangible-Book ranked lower than
59.84% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
OPNT: 3.19
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.12, Med: 3.3, Max: 2742.14
Current: 3.19
2.12
2742.14
Price-to-Projected-FCF 7.45
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
83.94% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
OPNT: 7.45
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 2.74, Med: 5.97, Max: 13.14
Current: 7.45
2.74
13.14
Price-to-Median-PS-Value 0.83
Price-to-Median-PS-Value ranked lower than
81.42% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
OPNT: 0.83
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.3, Med: 1.01, Max: 5.98
Current: 0.83
0.3
5.98
Earnings Yield (Joel Greenblatt) % -44.28
Earnings Yield (Greenblatt) ranked lower than
87.70% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
OPNT: -44.28
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -7658.5, Med: -48.4, Max: 533.7
Current: -44.28
-7658.5
533.7

More Statistics

Revenue (TTM) (Mil) $ 17.71
EPS (TTM) $ -4.06
Beta 0.33
Volatility % 65.64
52-Week Range $ 9.98 - 29.55
Shares Outstanding (Mil) 4

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y